Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

Gilles Crochet, Couturier Audrey, Emmanuel Bachy, Thomas Gastinne, Guillaume Cartron, Tom Fradon, Romain Gounot, Cristina Castilla-LLorente, Clementine Sarkozy, Vincent Camus, Stéphanie Guidez, Adrien Chauchet, Eric Deconinck, Krimo Bouabdallah, Franck Morschhauser, Roch Houot

Blood (2022) 140 (Supplement 1): 4639–4641.

DOI: https://doi.org/10.1182/blood-2022-162594

Published: 2022

Journal Articles

Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma

Clementine Sarkozy, Shaocheng Wu, Katsuyoshi Takata, Tomohiro Aoki, Susana Ben-Neriah, Katy Milne, Brad H Nelson, Andrew P. Weng, David W. Scott, Jeffrey W. Craig, Christian Steidl, Andrew Roth

Blood (2022) 140 (Supplement 1): 750–751.

DOI: https://doi.org/10.1182/blood-2022-160405

Published: 2022

Journal Articles

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Michael Nissen, Xuehai Wang, Clementine Sarkozy, Aixiang Jiang, Daisuke Ennishi, Tomohiro Aoki, Stacy Hung, Elizabeth Chavez, Jeffrey W Craig, Pedro Farinha, Graham W. Slack, David W. Scott, Christian Steidl, Andrew P. Weng

Blood (2021) 138 (Supplement 1): 719.

DOI: https://doi.org/10.1182/blood-2021-154082

Published: 2021

Journal Articles

Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories and Alternate Biologies in Human Follicular Lymphoma

Blood (2021) 138 (Supplement 1): 450.

DOI: https://doi.org/10.1182/blood-2021-153237

Published: 2021

Journal Articles

Characterization of DLBCL with a PMBL gene expression signature

Blood (2021) 138 (2): 136–148.

DOI: https://doi.org/10.1182/blood.2020007683

Published: 2021

Includes: Supplemental data

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

DOI: https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

DOI: https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

DOI: https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Gerben Duns, PhD, Elena Viganò, PhD, Daisuke Ennishi, MD PhD, Clementine Sarkozy, MD, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, MD PhD, Anja Mottok, MD PhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 922.

DOI: https://doi.org/10.1182/blood-2019-131450

Published: 2019

Journal Articles

Mutational Landscape of Grey Zone Lymphoma

Blood (2019) 134 (Supplement_1): 21.

DOI: https://doi.org/10.1182/blood-2019-127375

Published: 2019

Journal Articles

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Blood (2019) 134 (10): 802–813.

DOI: https://doi.org/10.1182/blood.2019001126

Published: 2019

Includes: Supplemental data

Journal Articles

Prognostic Biomarkers Converge on a Germinal Centre Dark Zone Phenotype As a Determinant of Adverse Outcome in Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy

Anjali Silva, PhD MSc, BSc, Clementine Sarkozy, MD, Tracy Lackraj, PhD BSc, Anja Mottok, Vindi Jurinovic, MSc, Laurie H Sehn, MD MPH, Oliver Weigert, MD, Christian Steidl, MD, Robert Kridel, PhD MD

Blood (2018) 132 (Supplement 1): 4095.

DOI: https://doi.org/10.1182/blood-2018-99-112689

Published: 2018

Journal Articles

A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers

Blood (2018) 132 (Supplement 1): 1629.

DOI: https://doi.org/10.1182/blood-2018-99-118578

Published: 2018

Journal Articles

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Sara Alonso, MD, Martina Manni, PhD, Clementine Sarkozy, MD, Marielle Wondergem, MD, Attilio Guarini, MD, Laura Magnano, MD, Miguel Alcoceba, PhD, Martine E.D. Chamuleau, MD, Sara Galimberti, Maria Gomes da Silva, MD, Harald Holte, MD PhD, Emanuele Zucca, MD, Silvia Montoto, MD, Sandra Lockmer, MD, Igor Aurer, MD PhD, Luigi Marcheselli, MSc, Dolores Caballero, MD, Gilles Salles, MD PhD, Massimo Federico, MD

Blood (2018) 132 (Supplement 1): 4145.

DOI: https://doi.org/10.1182/blood-2018-99-115956

Published: 2018

Journal Articles

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Clementine Sarkozy, MD, Franck Morschhauser, MD, Jean-Marie Michot, MD, Benjamin Suttle, Lionel Karlin, MD, Steven LE Gouill, MD PhD, Fabrice Jardin, MD PhD, Herve Tilly, MD, Charles Herbaux, MD, Gilles Andre Salles, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4191.

DOI: https://doi.org/10.1182/blood-2018-99-113193

Published: 2018

Journal Articles

Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University

Guillaume Aussedat, Delphine Maucort-Boulch, MD PhD, Philippe Rey, MD, Violaine Safar, MD, Lionel Karlin, MD, Mad-Helenie Elsensohn, Msc, Laure Lebras, MD, Clementine Sarkozy, MD, Emmanuel Bachy, MD PhD, Bertrand Favier, PharmD, PhD, Nicolas Vantard, PharmD, Pierre Sesques, MD, Anne Lazareth, MD, Emmanuelle Ferrant, MD, Dana Ghergus, MD, Gilles Salles, MD PhD, Emmanuelle Nicolas-Virelizier, MD, Herve Ghesquieres, MD PhD

Blood (2018) 132 (Supplement 1): 4215.

DOI: https://doi.org/10.1182/blood-2018-99-116734

Published: 2018

Journal Articles

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma

François Lemonnier, Jehan Dupuis, Pierre Sujobert, Olivier Tournillhac, Morgane Cheminant, Clémentine Sarkozy, Laura Pelletier, Ambroise Marçais, Cyrielle Robe, Virginie Fataccioli, Corinne Haioun, Olivier Hermine, Philippe Gaulard, Richard Delarue

Blood (2018) 132 (21): 2305–2309.

DOI: https://doi.org/10.1182/blood-2018-04-840538

Published: 2018

Includes: Supplemental data

Journal Articles

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Clementine Sarkozy, MD, Alexandra Traverse-Glehen, MD PhD, Emmanuel Bachy, Lionel Karlin, MD, Hervé Ghesquières, MD PhD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Gilles Salles, MD

Blood (2017) 130 (Supplement 1): 2770.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2770.2770

Published: 2017

Journal Articles

Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center

Guillaume Aussedat, Hervé Ghesquières, MD PhD, Aspasia Stamatoullas, MD, Pierre Hirsch, MDPhD, Emmanuelle Nicolas-Virelizier, MD, Guillaume Cartron, Caroline Regny, Lionel Karlin, MD, Catherine Chassagne-Clément, MD, Violaine Safar, Nicolas Albin, MD, Antoine Deleuze, Alexis Lambour, Nicolas Daguindau, Christiane Copie, MDPhD, Richard Lemal, MD, Gilles Salles, MD PhD, Alexandra traverse-Glehen, MD PhD, Clementine Sarkozy, MD

Blood (2017) 130 (Supplement 1): 4149.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4149.4149

Published: 2017

Journal Articles

The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study

Blood (2016) 128 (22): 1825.

DOI: https://doi.org/10.1182/blood.V128.22.1825.1825

Published: 2016

NARROW

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories and Alternate Biologies in Human Follicular Lymphoma

Characterization of DLBCL with a PMBL gene expression signature

Mutational landscape of gray zone lymphoma

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Mutational Landscape of Grey Zone Lymphoma

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Prognostic Biomarkers Converge on a Germinal Centre Dark Zone Phenotype As a Determinant of Adverse Outcome in Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy

A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center

The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only